Valuation
- Market cap
- 17,000
- Revenue TTM
- $0
- Net income TTM
- $-640,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- 0.00%
- Debt to equity
- -0.08
Trading
- Volume
- 100,000
- Avg volume
- —
- Day's range
- $0.00 – $0.00
- Shares out
- 165,770,000
- Stochastic %K
- 0%
- Beta
- -26.17
- Analysts
- —
- Price target
- —
Company profile
Regenicin, Inc., a biotechnology company, develops regenerative cell therapies to restore the health of damaged tissues and organs. Its product includes Tiscela, a tissue-engineered skin graft that utilizes a patient's own skin cells to create living, regenerative skin for treating severe burns and chronic wounds. The company was formerly known as Windstar, Inc. and changed its name to Regenicin, Inc. in July 2010. R...
Show more
Regenicin, Inc., a biotechnology company, develops regenerative cell therapies to restore the health of damaged tissues and organs. Its product includes Tiscela, a tissue-engineered skin graft that utilizes a patient's own skin cells to create living, regenerative skin for treating severe burns and chronic wounds. The company was formerly known as Windstar, Inc. and changed its name to Regenicin, Inc. in July 2010. Regenicin, Inc. was incorporated in 2007 and is headquartered in Las Vegas, Nevada.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 800 211 6348
- Website
- https://www.regenicin.com
- Address
- 3273 East Warm Springs Road, Las Vegas, United States
Latest news
No headlines yet.
